We tested the antitumor efficacy of Rimonabant in HCT116 and SW48 CRC cell lines, expressing APC and BRAF wild type and harbouring β-Catenin mutation (loss of phosphorylation site S45 and S33Y, respectively) and PIK3CA activating mutations. This evidence concerns the gene PIK3CA and colorectal carcinoma.